← Eichor
Study identifier: NCT05507242 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD

Condition: COPD · COPD Exacerbation · COPD Bronchitis  ·  Sponsor: Asger Sverrild

PhasePhase 2
Planned participants80
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.

This description comes directly from the study's public registry record.

Talk to the study team

Kristoffer Norheim, PhD  ·  +4542831337  ·  kristoffer.norheim@regionh.dk

Asger Sverrild, MD, PhD  ·  asger.sverrild@regionh.dk

Always discuss trial participation with your own doctor first.

Locations (2)

Research siteCopenhagen, DenmarkRecruiting
Research siteLeicester, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05507242